Skip to main content
main-content

Diabetes medications

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Featured podcast episode

ADA 2020 goes virtual!

Editorial Board Highlights

Listen to our Editorial Board reflecting on their highlights from the ADA scientific sessions, with discussion on the VERTIS-CV trial, diets for diabetes, insulin icodec and more (34:17).

medwireNews top story

Heart failure poses greatest CV mortality risk after type 2 diabetes diagnosis

Chalkboard image of patient with heart failure

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

Featured podcast episode

Expert commentary: Closed-loop insulin delivery research update

Rayhan Lal / concept image of pancreas

Engineer turned endocrinologist Rayhan Lal reflects on the shape of artificial pancreas research and what changes are needed to best benefit people with diabetes (18:54).

CME-accredited webcast

GLP-1RAs: Evidence From The Real World

Learn more about real world evidence of new GLP-1RAs, with Melanie Davies, Stewart Harris and Takashi Kadowaski.

ADA 2020

First weekly insulin shows equivalence with glargine in type 2 diabetes

Weekly calendar

A novel insulin that can be given as a once-weekly injection has achieved promising results in a randomized phase 2 trial involving people with type 2 diabetes.

ADA 2020

DPPOS: No change to cancer risk with long-term metformin use

Tablet device showing the chemical structure of Metformin

Among the latest findings from the DPP Outcomes Study is that long-term use of metformin does not affect the risk for cancer.

medwireNews top story

‘Compelling evidence’ of greater diabetes treatment inertia for ethnic minorities

Mixed diabetes medications

Doctors are faster to initiate pharmacologic type 2 diabetes treatment in people from ethnic minorities than in White people but are then slower to intensify their treatment when needed, show data from the UK.

The continuing evolution of GLP-1RAs – webcast available now!

The continuing evolution of GLP-1RAs

Don’t miss out on this expert-led webcast on the continuing evolution of glucagon-like peptide-1 receptor agonists, chaired by Professor John Wilding.

Expert opinion editorial

Oral semaglutide: A technical triumph, with caveats

Balancing pros and cons

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide [read more].

Get more on: Type 2 diabetes medications | GLP-1 receptor agonists

Podcast

Is oral semaglutide a game changer or nice-to-have for type 2 diabetes?

Neil Skolnik

US primary care physician Neil Skolnik discusses the role of oral semaglutide in the care of people with type 2 diabetes and outlines key considerations for its use (12:26) [Listen now]

Get more on: Type 2 diabetes medications | GLP-1 receptor agonists

06-24-2020 | ADA 2020 | Conference coverage | Article

ADA 2020 goes virtual! Editorial Board conference highlights

Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).

06-23-2020 | ADA 2020 | Podcast | Article

Expert commentary: Closed-loop insulin delivery research update

Engineer turned endocrinologist Rayhan Lal reflects on the shape of artificial pancreas research and what changes are needed to best benefit people with diabetes (18:54).

05-06-2020 | Type 2 diabetes | Editorial | Article

Oral semaglutide: A technical triumph, with caveats

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide.

Journal articles and book chapters

Learn about SGLT2 inhibitor use in type 2 diabetes management

Guidance from the Improving Diabetes Steering Committee

This content content collection includes details on:

  • A benefit/risk tool to inform prescribing decisions for SGLT2 inhibitors

  • The patient experience of diagnosis and self-management with SGLT2 inhibitors

  • Translating SGLT2 inhibitor cardiovascular evidence into practice
  • Key evidence and implications for clinical practice

This collection was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

The continuing evolution of GLP-1RAs

Chaired by John Wilding, with Julie Lovshin and Kamlesh Khunti, this webcast discusses the current and future treatment landscapes for type 2 diabetes focusing on once-weekly and next generation glucagon-like peptide‑1 receptor agonists.              

More

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits